Figure 2
Increased CD163-positive cells and poorer patient survival associated with alternative lengthening of telomeres with macrophages glioblastoma. (a) Examples of CD163 staining to illustrate tumors with increased CD163-positive cells in alternative lengthening of telomeres (ALT) tumors with increased macrophage/microglia gene signature by RNA-Seq. (b) Examples of CD163 staining in alternative lengthening of telomeres tumors without a macrophage/microglia gene signature by RNA-Seq to illustrate reduced CD163-positive cells. Inset: CD163-positive cells were found around blood vessels as part of the blood–brain barrier were used as a positive control. (c) An increased macrophage/microglia content in alternative lengthening of telomere-positive tumors was associated with poorer patient survival. ALT, alternative lengthening of telomeres tumors with reduced tumor-associated macrophages; ALTM, alternative lengthening of telomeres tumors with a high content of tumor-associated macrophages.
